Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'

Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like long-term adherence and physician conservatism. Biocon's Kiran Mazumdar-Shaw weighed in and urged caution, emphasizing diet and exercise as primary options for non-diabetic, non-obese individuals, citing potential long-term side effects of these…

The Economic Times

Grim Autopsy Details Torture As Morbidly Obese Seven-Year-Old Boy Weighing More Than Two Grown Men Suffers Fatal Agony

A Michigan couple faces murder and child abuse charges after their seven-year-old son died from heart failure linked to extreme obesity, highlighting severe neglect and household dysfunction.

International Business Times UK

'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugs

Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges with weekly injections and conservative doctor prescribing habits as key hurdles. The advent of oral alternatives might boost uptake, suggesting convenience and long-term commitment, rather than price, will drive future acceptance of…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

White House denies Donald Trump is the mystery patient receiving experimental obesity drug: ‘Idiotic question’

White House spokesperson says gossip that Trump is the patient is "baseless speculation."

We Got This Covered

Did Trump Get Experimental Obesity Drug? Rep Lieu Demands Answers Over FDA's 'Powerful Drug' Given to 'Unidentified 79-Year-Old Man'

Representative Ted Lieu questions the White House about claims that President Trump accessed an experimental obesity drug reserved for the gravely ill, sparking controversy and speculation.

International Business Times UK

Medicare's New $50 Weight Loss Drug Program Starts July 1 — but the Fine Print Could Surprise You

Medicare's GLP-1 Bridge starts July 1, 2026, with $50/month copays. But there are major fine-print limitations seniors need to know before signing up. Here's what to check.

Medical Daily

Trump Linked to Mystery FDA Deal Granting Early Access to Powerful Weight-Loss Drug for Critical Patients

A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide, sparking political and medical controversy amid speculation about the patient's identity.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April

A White House spokesman said theories that President Trump sought the drug were ‘baseless speculation’

The Independent UK

As Aussie waistlines expand, so do treatment costs

Most adult Australians are actually overweight or obese and that number is rising, research shows, with the problem taking a growing toll on health systems.

AAP

'It's not getting better': leading risk factor revealed for ill health and death

Almost 70 per cent of adults in Hunter New England are overweight or obese.

Newcastle Herald

ENDO 2026 Study Finds Most People Who Stop Ozempic or Tirzepatide for Type 2 Diabetes Eventually Restart Treatment

ENDO 2026 research published June 2026 via ScienceDaily found most GLP-1 users with type 2 diabetes who stop treatment eventually restart, driven by weight regain.

Medical Daily

Health company accused of using fake doctors for sales

Australians with diabetes, heart disease, obesity and menopause paid thousands and spoke with fake doctors who said their lives were at risk, a watchdog claims.

AAP

Ozempic Changed Obesity Treatment Forever — but Experts See a Bigger Medical Revolution Still Coming

A June 20, 2026 ScienceDaily report on a Gastroenterology commentary describes how GLP-1 drugs opened the door to a next era combining drugs, minimally invasive procedures, and precision medicine.

Medical Daily

Kids as young as six are being given weight-loss drugs as a way to curb obesity before it gets too late

About 21 percent of U.S. children between the ages of two and 19 have obesity, according to data from the Centers for Disease Control and Prevention

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Pfizer CFO Dave Denton to leave company in August

Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure raises investor concerns about Pfizer's 2026 forecast and succession plans. The company is preparing to enter the obesity drug market. Pfizer's shares were down in early trading. A search…

France 24

Not all skinny: The French do get fat

With the French healthcare system now reimbursing the anti-obesity drugs Wegovy and Mounjaro, we explain what the strict conditions are to benefit from them. We discuss France's rates of obesity and the areas where they're highest. Finally, we discuss the common stereotype that French people don't get fat. While not…

Medical Daily

GLP-1 Users Walk 560 Fewer Steps Per Day After Starting Ozempic or Wegovy, Fitbit Study Presented at ENDO 2026 Finds

ENDO 2026 study of 753 GLP-1 users found steps dropped 560/day and exercise fell 6 min/day after starting Ozempic or Wegovy. Muscle loss risk is the concern.

The Economic Times

India makes gains in child, maternal health but nutrition challenges persist: SBI report

India's latest health survey reveals significant improvements in maternal care and child vaccination rates. Stunting among children has seen a notable decline. However, modest gains in underweight and wasting indicate a need for comprehensive nutrition strategies. The survey also points to a rise in obesity among women. Fertility rates are…

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

A study presented at ASCO 2026 and published June 10, 2026 found that GLP-1 receptor agonists (semaglutide, tirzepatide) are associated with a 30–47% reduction in breast cancer risk among women with diabetes or obesity. The effect may operate through mechanisms beyond weight loss. Here is the full analysis.

The Economic Times

India risks becoming "unhealthier before it becomes richer," CEA V Anantha Nageswaran warns

India faces a health challenge before achieving wealth. Chief Economic Advisor V Anantha Nageswaran points to rising obesity and sedentary lifestyles. This impacts productivity and economic growth. He urges individuals to incorporate physical activity into daily routines. Improved health outcomes are seen as hidden growth potential for Viksit Bharat. This…

Fortune

Middle-aged adults taking GLP-1s for obesity can save $192K+ on lifetime medical costs, more if they don’t have college degrees, new study finds

The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access

The Economic Times

India's weight-loss drug boom raises questions over healthcare priorities

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns about misuse for cosmetic reasons are growing. Regulators are intervening in advertising. The drugs also have side effects and can lead to weight regain. This boom is impacting pharmaceutical research priorities.

The Economic Times

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Guardian - UK

Wegovy weight-loss pills to be available for patients in UK to buy

Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription

Medical Daily

Scientists Unveil a Diabetes and Obesity Pill That Burns Fat Through Muscle — Without Killing Your Appetite or Causing Muscle Loss

Karolinska/Stockholm University published a new obesity-diabetes pill in Cell (June 2026) that activates muscle metabolism to burn fat and lower blood sugar without appetite suppression or muscle loss. Safe in early human trial.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Centers for Disease Control and Prevention

239 stories

Novo

187 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.